4-(1,3-dioxo-2-isoindolyl)-N-(4-methyl-2-pyrimidinyl)benzenesulfonamide profile

ID Source	ID
PubMed CID	1116825
CHEMBL ID	483773
CHEBI ID	107933
SCHEMBL ID	2205824

Synonym
CBMICRO_000498
smr000171848
4-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-n-(4-methyl-pyrimidin-2-yl)-benzenesulfonamide
MLS000553625 ,
OPREA1_137913
BIM-0000459.P001
OPREA1_704102
4-(1,3-dioxo-1,3-dihydro-2h-isoindol-2-yl)-n-(4-methylpyrimidin-2-yl)benzenesulfonamide
STK332245
CHEBI:107933
CHEMBL483773
AKOS000714969
4-(1,3-dioxoisoindol-2-yl)-n-(4-methylpyrimidin-2-yl)benzenesulfonamide
smsf0008394
CB01734
SCHEMBL2205824
Q27186279
4-(1,3-dioxo-2-isoindolyl)-n-(4-methyl-2-pyrimidinyl)benzenesulfonamide
4-(1,3-dioxoisoindolin-2-yl)-n-(4-methylpyrimidin-2-yl)benzenesulfonamide
BRD-K06073311-001-08-3

Class	Description
phthalimides	A dicarboximide that is phthalimide or derivatives obtained from it by the formal replacement of one or more hydrogens.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE	Homo sapiens (human)	Potency	630.9570	0.0032	45.4673	12,589.2998	AID2517
ATAD5 protein, partial	Homo sapiens (human)	Potency	16.3601	0.0041	10.8903	31.5287	AID504467
vasopressin V1b receptor	Homo sapiens (human)	Potency	14.9478	0.1944	16.0180	43.6206	AID492948
relaxin receptor 1 isoform 1	Homo sapiens (human)	Potency	17.3335	0.0388	14.3501	43.6206	AID2676; AID489012
relaxin receptor 2 isoform 1	Homo sapiens (human)	Potency	18.8181	0.0488	15.9801	48.9431	AID489043
Guanine nucleotide-binding protein G	Homo sapiens (human)	Potency	25.1189	1.9953	25.5327	50.1187	AID624287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
negative regulation of inflammatory response to antigenic stimulus	Guanine nucleotide-binding protein G	Homo sapiens (human)
renal water homeostasis	Guanine nucleotide-binding protein G	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Guanine nucleotide-binding protein G	Homo sapiens (human)
regulation of insulin secretion	Guanine nucleotide-binding protein G	Homo sapiens (human)
cellular response to glucagon stimulus	Guanine nucleotide-binding protein G	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
G protein activity	Guanine nucleotide-binding protein G	Homo sapiens (human)
adenylate cyclase activator activity	Guanine nucleotide-binding protein G	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	Guanine nucleotide-binding protein G	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (40)

Assay ID	Title	Year	Journal	Article
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1179447	Genotoxicity in Salmonella typhimurium TA100 assessed as mutagenic index at 2 umol/plate	2014	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 24, Issue:14	Synthesis and evaluation of novel dapsone-thalidomide hybrids for the treatment of type 2 leprosy reactions.
AID1179420	Antinociceptive effect in mouse assessed as inhibition of acetic acid-induced abdominal constriction at 100 uM/kg, po	2014	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 24, Issue:14	Synthesis and evaluation of novel dapsone-thalidomide hybrids for the treatment of type 2 leprosy reactions.
AID1179438	Genotoxicity in Salmonella typhimurium TA102 assessed as mutagenic index at 8 umol/plate	2014	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 24, Issue:14	Synthesis and evaluation of novel dapsone-thalidomide hybrids for the treatment of type 2 leprosy reactions.
AID1179448	Genotoxicity in Salmonella typhimurium TA102 assessed as mutagenic index at 2 umol/plate in presence of S9 liver extract	2014	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 24, Issue:14	Synthesis and evaluation of novel dapsone-thalidomide hybrids for the treatment of type 2 leprosy reactions.
AID1179423	Antiinflammatory activity against mouse L929 cells assessed as inhibition of LPS-induced TNFalpha production at 15.625 uM after 48 hrs	2014	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 24, Issue:14	Synthesis and evaluation of novel dapsone-thalidomide hybrids for the treatment of type 2 leprosy reactions.
AID1179433	Genotoxicity in Salmonella typhimurium TA100 assessed as mutagenic index at 32 umol/plate in presence of S9 liver extract	2014	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 24, Issue:14	Synthesis and evaluation of novel dapsone-thalidomide hybrids for the treatment of type 2 leprosy reactions.
AID1179445	Genotoxicity in Salmonella typhimurium TA100 assessed as mutagenic index at 4 umol/plate in presence of S9 liver extract	2014	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 24, Issue:14	Synthesis and evaluation of novel dapsone-thalidomide hybrids for the treatment of type 2 leprosy reactions.
AID1179439	Genotoxicity in Salmonella typhimurium TA102 assessed as mutagenic index at 8 umol/plate in presence of S9 liver extract	2014	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 24, Issue:14	Synthesis and evaluation of novel dapsone-thalidomide hybrids for the treatment of type 2 leprosy reactions.
AID1179437	Genotoxicity in Salmonella typhimurium TA100 assessed as mutagenic index at 16 umol/plate in presence of S9 liver extract	2014	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 24, Issue:14	Synthesis and evaluation of novel dapsone-thalidomide hybrids for the treatment of type 2 leprosy reactions.
AID1179432	Genotoxicity in Salmonella typhimurium TA100 assessed as mutagenic index at 32 umol/plate	2014	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 24, Issue:14	Synthesis and evaluation of novel dapsone-thalidomide hybrids for the treatment of type 2 leprosy reactions.
AID1179421	Cytotoxicity against mouse L929 cells assessed as cell viability up to 150 uM	2014	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 24, Issue:14	Synthesis and evaluation of novel dapsone-thalidomide hybrids for the treatment of type 2 leprosy reactions.
AID1179435	Genotoxicity in Salmonella typhimurium TA102 assessed as mutagenic index at 16 umol/plate	2014	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 24, Issue:14	Synthesis and evaluation of novel dapsone-thalidomide hybrids for the treatment of type 2 leprosy reactions.
AID1179443	Genotoxicity in Salmonella typhimurium TA102 assessed as mutagenic index at 4 umol/plate in presence of S9 liver extract	2014	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 24, Issue:14	Synthesis and evaluation of novel dapsone-thalidomide hybrids for the treatment of type 2 leprosy reactions.
AID1179449	Genotoxicity in Salmonella typhimurium TA100 assessed as mutagenic index at 2 umol/plate in presence of S9 liver extract	2014	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 24, Issue:14	Synthesis and evaluation of novel dapsone-thalidomide hybrids for the treatment of type 2 leprosy reactions.
AID1179430	Genotoxicity in Salmonella typhimurium TA102 assessed as mutagenic index at 32 umol/plate	2014	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 24, Issue:14	Synthesis and evaluation of novel dapsone-thalidomide hybrids for the treatment of type 2 leprosy reactions.
AID1179444	Genotoxicity in Salmonella typhimurium TA100 assessed as mutagenic index at 4 umol/plate	2014	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 24, Issue:14	Synthesis and evaluation of novel dapsone-thalidomide hybrids for the treatment of type 2 leprosy reactions.
AID398142	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by Microplate Alamar blue assay	2009	Bioorganic & medicinal chemistry, Jun-01, Volume: 17, Issue:11	Synthesis and in vitro anti Mycobacterium tuberculosis activity of a series of phthalimide derivatives.
AID1179442	Genotoxicity in Salmonella typhimurium TA102 assessed as mutagenic index at 4 umol/plate	2014	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 24, Issue:14	Synthesis and evaluation of novel dapsone-thalidomide hybrids for the treatment of type 2 leprosy reactions.
AID1179434	Genotoxicity in Salmonella typhimurium TA102 assessed as mutagenic index at 16 umol/plate in presence of S9 liver extract	2014	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 24, Issue:14	Synthesis and evaluation of novel dapsone-thalidomide hybrids for the treatment of type 2 leprosy reactions.
AID1179425	Antimycobacterial activity against Mycobacterium leprae inoculated in mouse model assessed as mean number of bacilli at 200 mg/kg, po 5 days/week for 4 weeks (Rvb = 3.56 x 10'6 cells)	2014	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 24, Issue:14	Synthesis and evaluation of novel dapsone-thalidomide hybrids for the treatment of type 2 leprosy reactions.
AID1179440	Genotoxicity in Salmonella typhimurium TA100 assessed as mutagenic index at 8 umol/plate	2014	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 24, Issue:14	Synthesis and evaluation of novel dapsone-thalidomide hybrids for the treatment of type 2 leprosy reactions.
AID1179422	Antiinflammatory activity against mouse L929 cells assessed as inhibition of LPS-induced TNFalpha production at 125 uM after 48 hrs	2014	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 24, Issue:14	Synthesis and evaluation of novel dapsone-thalidomide hybrids for the treatment of type 2 leprosy reactions.
AID1179431	Genotoxicity in Salmonella typhimurium TA102 assessed as mutagenic index at 32 umol/plate in presence of S9 liver extract	2014	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 24, Issue:14	Synthesis and evaluation of novel dapsone-thalidomide hybrids for the treatment of type 2 leprosy reactions.
AID1179441	Genotoxicity in Salmonella typhimurium TA100 assessed as mutagenic index at 8 umol/plate in presence of S9 liver extract	2014	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 24, Issue:14	Synthesis and evaluation of novel dapsone-thalidomide hybrids for the treatment of type 2 leprosy reactions.
AID1179424	Antiinflammatory activity against mouse L929 cells assessed as inhibition of LPS-induced TNFalpha production after 48 hrs	2014	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 24, Issue:14	Synthesis and evaluation of novel dapsone-thalidomide hybrids for the treatment of type 2 leprosy reactions.
AID1179446	Genotoxicity in Salmonella typhimurium TA102 assessed as mutagenic index at 2 umol/plate	2014	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 24, Issue:14	Synthesis and evaluation of novel dapsone-thalidomide hybrids for the treatment of type 2 leprosy reactions.
AID1179436	Genotoxicity in Salmonella typhimurium TA100 assessed as mutagenic index at 16 umol/plate	2014	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 24, Issue:14	Synthesis and evaluation of novel dapsone-thalidomide hybrids for the treatment of type 2 leprosy reactions.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (28.57)	29.6817
2010's	4 (57.14)	24.3611
2020's	1 (14.29)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	7 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
2-aminofluorene [no description available]	2.1	1
dipyrone metamizole : A pyrazole that is antiipyrine substituted at C-4 by a methyl(sulfomethyl)amino group, the sodium salt of which, metamizole sodium, was widely used as a powerful analgesic and antipyretic, but withdrawn from many markets from the 1970s due to a risk of causing risk of causing agranulocytosis.	2.1	1	amino sulfonic acid; pyrazoles	anti-inflammatory agent; antipyretic; antirheumatic drug; cyclooxygenase 3 inhibitor; non-narcotic analgesic; peripheral nervous system drug; prodrug
isoniazid Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).	2.05	1	carbohydrazide	antitubercular agent; drug allergen
thalidomide Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.. thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.. 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.	2.1	1	phthalimides; piperidones
2-anthramine 2-anthramine: structure	2.1	1	anthracenamine
daunorubicin Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.	2.1	1	aminoglycoside antibiotic; anthracycline; p-quinones; tetracenequinones	antineoplastic agent; bacterial metabolite
sodium azide Sodium Azide: A cytochrome oxidase inhibitor which is a nitridizing agent and an inhibitor of terminal oxidation. (From Merck Index, 12th ed). sodium azide : The sodium salt of hydrogen azide (hydrazoic acid).	2.1	1	inorganic sodium salt	antibacterial agent; explosive; mitochondrial respiratory-chain inhibitor; mutagen

Condition	Relationship Strength	Studies
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1
Hansen Disease [description not available]	2.1	1
Leprosy A chronic granulomatous infection caused by MYCOBACTERIUM LEPRAE. The granulomatous lesions are manifested in the skin, the mucous membranes, and the peripheral nerves. Two polar or principal types are lepromatous and tuberculoid.	2.1	1

4-(1,3-dioxo-2-isoindolyl)-N-(4-methyl-2-pyrimidinyl)benzenesulfonamide

Cross-References

Synonyms (20)

Drug Classes (1)

Protein Targets (6)

Potency Measurements

Biological Processes (5)

Molecular Functions (2)

Ceullar Components (1)

Bioassays (40)

Research

Studies (7)

Market Indicators

Research Demand Index: 12.20

Study Types

4-(1,3-dioxo-2-isoindolyl)-N-(4-methyl-2-pyrimidinyl)benzenesulfonamide

Cross-References

Synonyms (20)

Drug Classes (1)

Protein Targets (6)

Potency Measurements

Biological Processes (5)

Molecular Functions (2)

Ceullar Components (1)

Bioassays (40)

Research

Studies (7)

Market Indicators

Research Demand Index: 12.20

Study Types

Related Drugs (7)

Related Conditions (4)